Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 6/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | ICMT | O60725 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 5/20 | 0.35 |
| ▸ | TLR4 | O00206 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23722056 | 0.99 | IDO1 (0.40) | IDO1EPHX2CNR1CNR2ICMT | |
| SCHEMBL23745893 | 0.95 | IDO1 (0.45) | IDO1EPHX2CNR1CNR2ICMT | |
| SCHEMBL23722118 | 0.93 | IDO1 (0.42) | IDO1EPHX2CNR1CNR2ICMT | |
| SCHEMBL23745585 | 0.93 | CNR2 (0.46) | IDO1EPHX2CNR1CNR2ICMT | |
| Hydrochloric Acid SCHEMBL23721976 | 0.92 | CNR2 (0.45) | IDO1EPHX2CNR1CNR2ICMT | |
| SCHEMBL23745611 | 0.91 | CNR1 (0.37) | IDO1EPHX2CNR1CNR2ICMT | |
| SCHEMBL23745552 | 0.91 | IL1B (0.39) | IDO1EPHX2CNR1CNR2ICMT | |
| SCHEMBL23745682 | 0.91 | CNR1 (0.38) | CNR1ICMTKMT2ACCR1CYP3A4 | |
| SCHEMBL23745695 | 0.91 | IDO1 (0.40) | IDO1EPHX2CNR1CNR2ICMT | |
| SCHEMBL23745464 | 0.91 | CNR1 (0.41) | CNR1CNR2ICMTKMT2ACCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246115-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | FDPS, FPR1, F12 | IDO1 1282/4885EPHX2 627/4885CNR1 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.